KOLMAR-BNH
HemoHim, a health functional food developed by Kolmar BNH (KRX: 200130), is garnering significant attention in the global market thanks to its meticulous quality control measures throughout the entire process, starting with the stringent management of raw material origins.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823112347/en/
HemoHim G, produced by Kolmar BNH and distributed by Atomy is gaining a great popularity around the world (Image: Kolmar BNH)
HemoHim is Korea's first individually-approved health functional food designed to enhance immune function and alleviate fatigue. Developed by Kolmar BNH in 2006, it is formulated with domestic natural ingredients such as angelica gigas, cnidium officinale, and paeonia japonica. Distributed by Atomy, HemoHim is exported to about 20 countries, including the United States and China. Since its launch, it has generated over KRW 2 trillion in cumulative domestic and international sales, with exports surpassing USD 200 million.
HemoHim's nearly 20-year consumer preference is highly attributed to the "trust earned through rigorous quality control." Kolmar BNH, the manufacturer of HemoHim, maintains strict oversight over the cultivation of its primary raw materials—Korean angelica gigas Nakai, cnidium officinale, paeonia japonica—ensuring their safety. The company has established a dedicated food safety team to continuously share technology and provide education to raw material cultivating farms, while rigorously inspecting the safety, stability, and efficacy of these ingredients.
Furthermore, Kolmar BNH has enhanced its quality competitiveness by developing genetic testing methods to verify the country of origin, ensuring the prevention of contamination of primary raw materials with other species. In July, Kolmar BNH patented a genetic analysis method (SCAR Marker) that identifies the origin of Korean angelica gigas by recognizing specific genetic regions. Moreover, Kolmar BNH developed a genetic analysis method using PCR (polymerase chain reaction) analysis for cnidium officinalea and paeonia japonica and completed the patent registration process two years ago.
Safety was also the top priority for HemoHim G, a latest product targeting the global market. In April, Kolmar BNH published a study on HemoHim G in the SCIE-ranked journal ‘Toxicological Research,’ demonstrating its safety. Conducted according to OECD guidelines, the study holds significance not only in facilitating safety approvals in other countries but also in securing intellectual property rights with reliable results.
HemoHim G (Global) is the international version of HemoHim, Korea’s first individually-approved immune-boosting health supplement developed by Kolmar BNH over an eight-year period. The formulation has been tailored to comply with the food regulations of various countries, with adjustments made to raw materials and ingredient ratios. The product features angelica sinensis, ligusticum chuanxiong, paeonia lactiflora, all selected through rigorous provenance and quality control processes. Enhanced taste and aroma also make HemoHim G more appealing to a broader audience.
Kolmar BNH plans to continuously improve quality through ongoing research and development to support HemoHim's growth as a globally recognized brand.
"HemoHim, now established as a leading K-health functional food brand in the global market, is manufactured through an exhaustive quality control process,” A Kolmar BNH official said. “We will continue to conduct extensive research and development to further enhance product reliability.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240823112347/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom